# Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

> **NCT06290349** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 174 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** DA5221-T1
- **DRUG:** DA5221-T2
- **DRUG:** Placebo
- **DRUG:** DA5221-B1
- **DRUG:** DA5221-B2

## Key facts

- **NCT ID:** NCT06290349
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2025-09-05
- **Final completion:** 2026-03-31
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06290349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06290349, "Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06290349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*